Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03771508 · ClinicalTrials.gov registry record
Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 3,712
- Enrollment target
NCT03771508: Completed study, sponsored by Medtronic - MITG.
NCT03771508 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 3,712 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03771508 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 3,712 participants
- Enrollment target
Study Summary
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
Primary Outcome
sponsor database will be expanded with images of pathologies and normal mucosa for future development and validation of improved algorithms for GI pathologies detection with the PillCam platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,712 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2025-09-30 |
What the finished NCT03771508 record still lists
NCT03771508 is an observational study that tracks outcomes without assigning an intervention. Its 3,712 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03771508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03771508 about?
NCT03771508 is a clinical study titled "Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)". Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
What is the current status of trial NCT03771508?
This trial is currently completed. The enrollment target is 3,712 participants. The study started on 2018-12-13. Estimated completion is 2025-09-30.
Who is sponsoring clinical trial NCT03771508?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06076304 · 3,720 participants · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI